A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2

被引:0
|
作者
Yang Liu [1 ]
Yan Liu [2 ]
Kaiyin Yang [3 ]
Zhiruo Zhang [1 ]
Wenbo Zhang [1 ]
Bingyou Yang [2 ]
Hua Li [1 ,4 ]
Lixia Chen [1 ]
机构
[1] Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University
[2] Key Laboratory of Basic and Application Research of Beiyao, Ministry of Education, Heilongjiang University of Chinese Medicine
[3] Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology
[4] Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Hexokinase 2(HK2) is the rate-limiting enzyme in the first step of glycolysis, catalyzing glucose to glucose-6-phosphate, and overexpressed in most cancer cells. HK2 also binds to voltage-dependent anion channel(VDAC) to stabilize the mitochondrial outer membrane, which inhibits cancer cell apoptosis.Therefore, HK2 has become a potential target for cancer treatment. Proteolysis targeting chimeras(PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation. Many potent and specific PROTACs targeting dissimilar targets have been developed. In this study, an HK2 PROTAC, 4H-5P-M, was developed and induced the degradation of HK2 relying on the ubiquitin-proteasome system. It was found that 4H-5P-M as an effective HK2 degrader induced HK2 degradation in a dose-and time-dependent manner and suppressed the growth of SW480 cells. 4H-5P-M selectively induced HK2 degradation at a lower concentration than other hexokinase isozymes. Moreover, it could suppress glycolysis and accelerate the apoptosis of cancer cells. Therefore, it provided a new insight into the development of anti-tumor drugs.
引用
收藏
页码:228 / 231
页数:4
相关论文
共 50 条
  • [31] Glycolysis Back in the Limelight: Systemic Targeting of HK2 Blocks Tumor Growth
    Ros, Susana
    Schulze, Almut
    CANCER DISCOVERY, 2013, 3 (10) : 1105 - 1107
  • [32] PLOD2 promotes aerobic glycolysis and cell progression in colorectal cancer by upregulating HK2
    Du, Wenwu
    Liu, Ning
    Zhang, Yafeng
    Liu, Xi
    Yang, Yuanhong
    Chen, Wei
    He, Yi
    BIOCHEMISTRY AND CELL BIOLOGY, 2020, 98 (03) : 386 - 395
  • [33] Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2)
    Jiao, Lin
    Zhang, Hai-Liang
    Li, Dan-Dan
    Yang, Ke-Li
    Tang, Jun
    Li, Xuan
    Ji, Jiao
    Yu, Yan
    Wu, Rui-Yan
    Ravichandran, Senthilkumar
    Liu, Jian-Jun
    Feng, Gong-Kan
    Chen, Min-Shan
    Zeng, Yi-Xin
    Deng, Rong
    Zhu, Xiao-Feng
    AUTOPHAGY, 2018, 14 (04) : 671 - 684
  • [34] Free and total human glandular kallikrein 2 (hk2) in prostate cancer patients
    Väisänen, V
    Alanen, K
    Nurmi, M
    Pettersson, K
    CLINICA CHIMICA ACTA, 2005, 355 : S432 - S433
  • [35] Complex linear differential equations with solutions in the HK2 spaces
    Sun, Yu
    Liu, Jinlin
    Hu, Guangming
    COMPLEX VARIABLES AND ELLIPTIC EQUATIONS, 2022, 67 (11) : 2577 - 2588
  • [36] Increased expression of human Kallikrein (hK2) in moderate grade prostate cancer
    Sejima, T
    Miyagawa, I
    True, LD
    Finlay, JA
    Rittenhouse, HG
    Felise, DG
    Vessella, RL
    Lange, PH
    Ellis, WJ
    Roudier, M
    Takayama, TK
    JOURNAL OF UROLOGY, 2002, 167 (04): : 230 - 230
  • [38] Human kallikrein 2 (HK2) inhibitors suppress tumor growth of prostate cancer xenografts in nude mice
    Kündig, C
    Cloutier, SM
    Aellen, S
    Felber, LM
    Chagas, JR
    Gygi, CM
    Jichlinski, P
    Leisinger, HJ
    Diamandis, EP
    Deperthes, D
    JOURNAL OF UROLOGY, 2006, 175 (04): : 263 - 263
  • [39] FUNCTIONAL AND STRUCTURAL ANALYSES OF PEPTIDES BINDING TO HUMAN KALLIKREINS HK2 AND HK3
    Pakkala, M. P.
    Wu, P.
    Leinonen, J.
    Stenman, U. H.
    Vepsalainen, J.
    Narvanen, A.
    JOURNAL OF PEPTIDE SCIENCE, 2004, 10 : 166 - 166
  • [40] HK2 in microglia and macrophages contribute to the development of neuropathic pain
    Wang, Siyuan
    Jiang, Chao
    Cao, Kelei
    Li, Run
    Gao, Zhihua
    Wang, Yue
    GLIA, 2024, 72 (02) : 396 - 410